A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)

Trial Profile

A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Vesigenurtucel-L (Primary) ; BCG
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Heat Biologics
  • Most Recent Events

    • 06 Jun 2017 Results assessing the secondary immune outcomes (immune response results), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 Results published in a Heat Biologics media release.
    • 11 May 2017 According to a Heat Biologics media release, the company is discontinuing non-muscle invasive bladder cancer program due to change in priority. The company will reallocate resources towards combination program.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top